Trials / Completed
CompletedNCT05793450
Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess how fast IBI362 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI362 | 2.0mg, SC, single dose |
Timeline
- Start date
- 2023-05-05
- Primary completion
- 2023-09-18
- Completion
- 2023-11-17
- First posted
- 2023-03-31
- Last updated
- 2024-02-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05793450. Inclusion in this directory is not an endorsement.